AXSM Axsome Therapeutics, Inc.
Price Chart
Executive Summary
Axsome Therapeutics announced presentations of new SYMBRAVO® data at the AHS 68th Annual Scientific Meeting, including post-hoc efficacy analyses and a network meta-analysis comparing SYMBRAVO to gepants for acute migraine treatment. This is a routine scientific conference update with no new regulatory or financial catalysts.
Actionable Insight
This is a routine medical conference update with no material new data or regulatory catalyst. Monitor for any subsequent peer-reviewed publications or label expansion announcements, but no immediate trading action warranted.
Key Facts
- Presentations at AHS 68th Annual Scientific Meeting, June 4-7 in Orlando, FL
- Four SYMBRAVO data presentations: post-hoc composite efficacy, network meta-analysis vs. gepants, sustained pain relief analysis, and safety endpoint analysis
- No new clinical trial results, regulatory decisions, or financial guidance provided
- SYMBRAVO is already FDA-approved for acute treatment of migraine
Financial Impact
No financial figures disclosed; routine scientific conference update
Risk Factors
- No new efficacy or safety signals disclosed that could change competitive positioning
- Network meta-analysis vs. gepants may not be considered definitive by prescribers
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306621 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
1d ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Jun 3, 2026
2d ago
|
8-K
| $233.49 awaiting T+20 | awaiting T+20 | — | $233.12 (−0.16%) |
|
May 4, 2026
4w ago
|
8-K
| $223.70 $230.25 | ▲ +2.93% | ▼ −2.72% | $233.12 (+4.21%) |
|
May 4, 2026
4w ago
|
Press Release
| $223.70 $230.25 | ▲ +2.93% | ▼ −2.72% | $233.12 (+4.21%) |
|
May 1, 2026
5w ago
|
Press Release
| $206.53 $230.25 | ▲ +11.48% | ▲ +6.20% | $233.12 (+12.87%) |
|
Apr 30, 2026
5w ago
|
8-K
| $206.53 $230.25 | ▲ +11.48% | ▲ +6.20% | $233.12 (+12.87%) |
|
Apr 30, 2026
5w ago
|
Press Release
| $207.75 $232.83 | ▲ +12.07% | ▲ +7.10% | $233.12 (+12.21%) |
|
Apr 24, 2026
5w ago
|
DEFA14A
| $187.40 $234.20 | ▲ +24.97% | ▲ +20.02% | $233.12 (+24.40%) |
|
Apr 8, 2026
8w ago
|
Press Release
| $173.19 $223.06 | ▲ +28.80% | ▲ +20.25% | $233.12 (+34.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access